ストックスクリーナーアプリを入手
0.6319
5.32%
0.0319
前日終値:
$0.60
開ける：
$0.62
24時間の取引高:
3.05M
Relative Volume:
2.39
時価総額：
$58.06M
収益：
-
当期純損益:
$-40.23M
株価収益率:
-1.4781
EPS:
-0.4275
ネットキャッシュフロー:
$-34.82M
1週間 パフォーマンス:
-55.50%
1か月 パフォーマンス:
-70.61%
6か月 パフォーマンス:
-45.05%
1年 パフォーマンス:
+12.10%
1日の値動き範囲:
$0.5893
$0.6373
1週間の範囲:
$0.5818
$1.51
52週間の値動き範囲:
$0.56
$3.62
Context Therapeutics Inc Stock (CNTX) Company Profile
名前
Context Therapeutics Inc
セクター
電話
267-225-7416
住所
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.6319 | 58.06M | 0 | -40.23M | -34.82M | -0.4275 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-18 | 開始されました | Guggenheim | Buy |
| 2025-04-21 | 開始されました | William Blair | Outperform |
| 2025-01-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-11-25 | 開始されました | D. Boral Capital | Buy |
| 2024-05-16 | 開始されました | Piper Sandler | Overweight |
Context Therapeutics Inc (CNTX) 最新ニュース
Context Therapeutics Inc (CNTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Context Therapeutics Inc (CNTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Context Therapeutics Inc (CNTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Context Therapeutics Inc (CNTX) Institutional Confidence - TradingKey
Context Therapeutics Inc (CNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Context Therapeutics Inc (CNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Context Therapeutics Inc (CNTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Context Therapeutics Inc (CNTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CNTX Maintained by Maxim Group -- Price Target Lowered to $4.00 - GuruFocus
CNTX Stock Price, Quote & Chart - ChartMill
Analysts Offer Insights on Healthcare Companies: Dyadic International (DYAI) and Context Therapeutics (CNTX) - The Globe and Mail
EBIT per share of Context Therapeutics, Inc. – DUS:6K9 - TradingView
Basic earnings per share (basic EPS) of Context Therapeutics, Inc. – DUS:6K9 - TradingView
Context Therapeutics, Inc. Balance Sheet – DUS:6K9 - TradingView
Cost of goods sold of Context Therapeutics, Inc. – DUS:6K9 - TradingView
Context Therapeutics Inc (CNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip - Stocktwits
Small biotech Context Therapeutics reports 29% response rate in ovarian cancer study - MSN
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Context Therapeutics Announces Positive Inter - Moomoo
Context Therapeutics rises on interim Phase 1 ovarian cancer data - grafa.com
Context Therapeutics Reports Encouraging Phase 1 Results for CTIM-76 T Cell Engager in Platinum-Resistant Ovarian Cancer – Minichart - Minichart
CNTX: CTIM-76 achieved a 29% response rate and low-grade CRS in heavily pretreated PROC patients - TradingView
Context reports positive interim Phase 1 CTIM-76 data with 29% ORR in PROC, low CRS - TradingView
Context Therapeutics (NASDAQ: CNTX) shows early CTIM-76 activity in platinum-resistant ovarian cancer - Stock Titan
Context Therapeutics to Proceed With Next Development Phase of CTIM-76 in Ovarian Cancer - Moomoo
CNTX: CTIM-76 shows 29% response and strong safety in late-line platinum-resistant ovarian cancer - TradingView
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76 - The Manila Times
Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76 - TradingView
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase ... - Caledonian Record
New CTIM-76 data show tumor responses in platinum-resistant ovarian cancer - Stock Titan
Context Therapeutics Grants New-Hire Equity Award Under Nasdaq Rule - MyChesCo
CNTX Q1 2026 Earnings: Narrower Loss Beats Estimates as Context Therapeutics Advances Clinical PipelinePost-Announcement Reaction - newsline.com
Context Therapeutics | 8-K: Current report - Moomoo
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Context Therapeutics (CNTX) - The Globe and Mail
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
JonesTrading Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
CNTX Q1 2026 Earnings: EPS Beat Amid Operational Progress; Stock DeclinesEarnings Stability Report - newsline.com
Context Therapeutics (CNTX) Sheds 13.8% as Stock Tests Key Support LevelLow Beta Factor - newsline.com
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
CNTX News | CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) - ChartMill
Monopar Therapeutics Inc (MNPR) Receives a Buy from Piper Sandler - The Globe and Mail
Piper Sandler Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
- The Legal Advocate
Context Therapeutics (CNTX) Edges Higher, Tests Resistance Near $3.00Impulse Wave - The Legal Advocate
Gyre Therapeutics (GYRE) Gains Momentum: Price Nears Key Resistance at $6.21Equal Weight ETF - The Legal Advocate
Context Therapeutics (CNTX) Holds Near Support as Biotech Sector Faces HeadwindsVolume Rate Change - The Legal Advocate
CNTX Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SurpriseRevenue Estimate Trend - The Legal Advocate
Context Therapeutics Gains 34%, Insider Trades Reap Benefit - 富途牛牛
CNTX Q1 2026 Earnings: Narrower Loss Surprises, Shares Advance Over 13%Estimate Accuracy - The Legal Advocate
Context Therapeutics Inc (CNTX) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):